Abstract:ejd.2013.1991 Auteur(s) : Axel Patrice Villani, Daniela Zaharia, Stephane Dalle, Laurianne Depaepe, Brigitte Balme, Luc Thomas [email protected] Department of Dermatology, Lyon 1 University, Cent...ejd.2013.1991 Auteur(s) : Axel Patrice Villani, Daniela Zaharia, Stephane Dalle, Laurianne Depaepe, Brigitte Balme, Luc Thomas [email protected] Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud, 69495 Pierre Benite Cedex, France Vemurafenib, the first selective BRAF inhibitor, is indicated to treat patients with unresectable or metastatic melanoma with the BRAFV600E mutation [1]. This drug is associated with remarkable dermatological adverse effects (skin rash, photosensitivity, squamous-cell [...]Read More
Publication Year: 2013
Publication Date: 2013-03-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 14
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot